ArticlePublisher preview available

Aryloxy Triester Phosphoramidates as Phosphoserine Prodrugs: A Proof of Concept Study

Wiley
ChemMedChem
Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract and Figures

The specific targeting of protein‐protein interactions by phosphoserine‐containing small molecules has been scarce due to the dephosphorylation of phosphoserine and its charged nature at physiological pH, which hinder its uptake into cells. To address these issues, we herein report the synthesis of phosphoserine aryloxy triester phosphoramidates as phosphoserine prodrugs that are enzymatically metabolized to release phosphoserine. This phosphoserine‐masking approach was applied to a phosphoserine‐containing inhibitor of 14‐3‐3 dimerization, and the generated prodrugs exhibited improved pharmacological activity. Collectively, this provided a proof of concept that the masking of phosphoserine with biocleavable aryloxy triester phosphoramidate masking groups is a viable intracellular delivery system for phosphoserine‐containing molecules. Ultimately, this will facilitate the discovery of phosphoserine‐containing small‐molecule therapeutics.
This content is subject to copyright. Terms and conditions apply.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Aryloxy Triester Phosphoramidates as Phosphoserine
Prodrugs: A Proof of Concept Study
Ageo Miccoli,[a] Binar A. Dhiani,[a] Peter J. Thornton,[b] Olivia A. Lambourne,[a] Edward James,[a]
Hachemi Kadri,[c] and Youcef Mehellou*[a]
The specific targeting of protein-protein interactions by
phosphoserine-containing small molecules has been scarce due
to the dephosphorylation of phosphoserine and its charged
nature at physiological pH, which hinder its uptake into cells. To
address these issues, we herein report the synthesis of
phosphoserine aryloxy triester phosphoramidates as phospho-
serine prodrugs that are enzymatically metabolized to release
phosphoserine. This phosphoserine-masking approach was
applied to a phosphoserine-containing inhibitor of 14-3-3
dimerization, and the generated prodrugs exhibited improved
pharmacological activity. Collectively, this provided a proof of
concept that the masking of phosphoserine with biocleavable
aryloxy triester phosphoramidate masking groups is a viable
intracellular delivery system for phosphoserine-containing mol-
ecules. Ultimately, this will facilitate the discovery of phospho-
serine-containing small-molecule therapeutics.
Protein phosphorylation at serine residues is a fundamental
phenomenon that is used by cells to affect the function,
localization and degradation of proteins.[1] In some cases,
phosphorylated serine residues mediate protein-protein inter-
actions via the docking of the phosphoserine residue into a
positively charged pocket within the partner protein. An
example of this is the serine phosphorylation of the adaptor
protein 14-3-3, which facilitates its homodimerization.[2] At-
tempts at inhibiting these phosphoserine-mediated protein-
protein interactions with small molecules have mostly led, by
design, to small molecules that lack phosphoserine. The move
to discard phosphoserine groups from these molecules was
driven by the fact that phosphoserine carries two negative
charges at physiological pH, which limit its (passive) cellular
uptake.[3] Additionally, phosphoserine is also subject to dephos-
phorylation by alkaline phosphatases, a process that yields
serine-containing derivatives that do not often retain potent
pharmacological activity compared to their parent phosphoser-
ine-containing molecules. Although the masking of the
phosphate group of phosphoserine was previously investigated,
the study was limited to a phosphoserine mimetic
(difluoromethylenephosphoserine) and not the natural phos-
phoserine moiety.[4] With this in mind and in order to improve
the drug-like properties of phosphoserine-containing small
molecules, we explored the application of the aryloxy triester
phosphoramidate technology to phosphoserine. This technol-
ogy has been widely used to mask the 5’-O-monophosphate
groups of nucleotides, and has so far led to two FDA-approved
drugs; sofosbuvir and tenefovir alafenamide.[5]
As a proof of concept, we initially synthesized phosphoser-
ine with the aryloxy triester phosphoramidate masking groups
(Figure 1 a). For this, the N- and C-terminals of phosphoserine
had to be protected[6] first to allow for the selective addition of
the aryloxy triester phosphoramidate moiety to the side chain
hydroxyl group. The synthesis was initiated by the chlorination
of tert-butanol (1) by copper(I) chloride with the peptide
coupling reagent N,N-dicyclohexylcarbodiimide (DCC).[6] The
generated compound, 2, was then reacted with the commer-
cially available N-Boc L-serine, 3, in DCM to yield the N- and C-
protected L-serine 4.[6] This latter compound was subsequently
reacted with phenyl L-alanine methyl ester phosphorochlor-
idate (7), which had been synthesized according to reported
procedures[7] by reacting L-alanine methyl ester hydrochloride
(6) with the commercially available phenyl dichlorophosphate
(5) in DCM and in the presence of triethylamine (NEt3). This
reaction yielded the desired phosphoserine aryloxy triester
phosphoramidate, compound 8, as a white solid in a good yield
(62 %).
With the phosphoserine aryloxy triester phosphoramidate in
hand, we first studied whether the aryl and amino acid ester
groups that mask the phosphate group of phosphoserine could
be metabolized in vitro to release the unmasked phosphoserine
species. It is now well established that the metabolism of the
aryloxy triester phosphoramidate moieties is initiated by the
cleavage of the ester motif by carboxypeptidase Y to yield
metabolite A(Figure 1 b).[5a,8]
The formed carboxylate group then performs a nucleophilic
attack onto the phosphate group leading to the release of the
aryl group and the formation of a highly unstable five-
membered anhydride ring (metabolite B, Figure 1 b). This is
subsequently opened up by a water molecule to generate the
phosphoramidate metabolite C(Figure 1 b). Finally, the phos-
phoramidase-type enzyme Hint-1[9] cleaves the PN bond of
[a] Dr. A. Miccoli, Dr. B. A. Dhiani, O. A. Lambourne, Dr. E. James,
Dr. Y. Mehellou
School of Pharmacy and Pharmaceutical Sciences
Cardiff University
King Edward VII Avenue, Cardiff, CF10 3NB (UK)
E-mail: MehellouY1@cardiff.ac.uk
[b] Dr. P. J. Thornton
Technology Solutions GBU, Solvay Solutions
Oldbury, B69 4LN (UK)
[c] Dr. H. Kadri
Department of Chemistry, Durham University
South Road, Durham, DH1 3LE (UK)
Supporting information for this article is available on the WWW under
https://doi.org/10.1002/cmdc.202000034
ChemMedChem
Communications
doi.org/10.1002/cmdc.202000034
671ChemMedChem 2020,15, 671– 674 © 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Dienstag, 14.04.2020
2008 / 162173 [S. 671/674] 1
... The spectroscopic analyses confirmed the structures of the newly synthesized compounds, which were subsequently evaluated in vitro for their ability to inhibit the pancreatic α-amylase enzyme. [58] Miccoli et al. [59] developed a method in 2020 for the synthesis of phosphoserine with aryloxy triester phosphoramidate masking groups. The synthetic approach involved protecting the N-and C-terminals of phosphoserine to enable selective addition of the aryloxy triester phosphoramidate group to the hydroxyl side chain. ...
Article
Full-text available
Organophosphorus compounds (OPs) are a diverse group of chemical compounds that contain organic moieties directly bonded to phosphorus or through a heteroatom like oxygen, nitrogen, or sulfur. They are ubiquitous in the human environment due to their unique properties and high biological activity. OPs have been widely used in various fields such as agriculture (as pesticides), industry (for producing lubricants, hydraulic fluids, and plastics), medicine (as drugs against osteoporosis, anticancer, and antiviral compounds), and veterinary (as anthelmintics). As an important class of organophosphorus compounds, this review provides an overview of phosphoramidate compounds covering their synthetic pathways, a brief explanation of their mechanisms, and their various applications.
... Our objective was to study the impact of the overall charge of the trackable therapeutic agent (or theranostic) on its biological properties. Indeed, it has been shown that it can have an impact on the cellular uptake [47], the mode of transport in the cells [48], etc. At physiological pH, azaBODI-Au-1 possesses two positive charges (two ammonium arms), azaBODI-Au-2 can be charged 4þ (two ammonium arms and protonation of the two NMe 2 groups brought by the thiolato ligand), and azaBODI-Au-3 is neutral (two ammonium arms and two negative charges brought by the two sulfonates). ...
Article
Three near-infrared (NIR-I) optical theranostic systems were synthesized, characterized and studied in vitro and in vivo. These original homo-bimetallic gold(I)-based aza-BODIPY complexes proved to be trackable through near-infrared optical imaging in cells and in mice. They display anti-proliferative properties in micromolar range against human and murine cancer cell lines (4T1, MDA-MB-231, CT26, and SW480). Moreover, the injection of the most promising theranostic agent in CT26 tumor-bearing BALB/c mice induced a significant anti-cancer activity.
Chapter
This annual review of the literature provides a comprehensive and critical survey of a vast field of study involving organophosphorus compounds, ranging from phosphines, their chalcogenide derivatives and phosphonium salts, phosphorus (III) acid derivatives, phosphorus (V) acids, penta- and hexa-coordinated phosphorus compounds, phosphazenes and related phosphorus-nitrogen bonded compounds. Coverage in applications as reagents in green synthetic procedures is also given. With an emphasis on interdisciplinary content, this book will appeal to the worldwide organic chemistry and engineering research communities.
Article
Full-text available
Phosphorus‐based self‐immolative (SI) linkers offer a wide range of applications, such as smart materials and drug‐delivery systems. Phosphorus SI linkers are ideal candidates for double‐cargo delivery platforms because they have a higher valency than carbon. A series of substituted phosphate linkers was designed for releasing two phenolic cargos through SI followed by chemical hydrolysis. Suitable modifications of the lactate spacer increased the cargo release rate significantly, from 1 day to 2 hours or 5 minutes, as shown for linkers containing p‐fluoro phenol. In turn, double cargo linkers bearing p‐methyl phenol released their cargo more slowly (4 days, 4 hours, and 15 minutes) than their p‐fluoro analogues. The α‐hydroxyisobutyrate linker released both cargos in 25 minutes. Our study expands the current portfolio of SI constructs by providing a double cargo delivery option, which is crucial to develop universal SI platforms.
Article
Introduction The ProTide technology is a phosphate (or phosphonate) prodrug method devised to deliver nucleoside monophosphate (or monophosphonate) intracellularly bypassing the key challenges of antiviral and anticancer nucleoside analogues. Three new antiviral drugs, exploiting this technology, have been approved by the FDA while others are in clinical studies as anticancer agents. Areas covered The authors describe the origin and development of this technology and its incredible success in transforming the drug discovery of antiviral and anticancer nucleoside analogues. As evidence, discussion on the antiviral ProTides on the market, and those currently in clinical development is included. The authors focus on how the proven capacity of this technology to generate new drug candidates has stimulated its application to non-nucleoside-based molecules. Expert opinion The ProTide approach has been extremely successful in delivering blockbuster antiviral medicines and it seems promising in oncology. Its application to non-nucleoside-based small molecules is recently emerging and proving effective in other therapeutic areas. However, investigations to explain the lack of activity of certain ProTide series and comprehensive structure activity relationship studies to identify the appropriate phosphoramidate motifs depending on the parent molecule are in our opinion mandatory for the future development of these compounds.
Article
Full-text available
A phosphoramidate prodrug of 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate, PSI-7851, demonstrates potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. PSI-7851 is a mixture of two diastereoisomers, PSI-7976 and PSI-7977, with PSI-7977 being the more active inhibitor of HCV RNA replication in the HCV replicon assay. To inhibit the HCV NS5B RNA-dependent RNA polymerase, PSI-7851 must be metabolized to the active triphosphate form. The first step, hydrolysis of the carboxyl ester by human cathepsin A (CatA) and/or carboxylesterase 1 (CES1), is a stereospecific reaction. Western blot analysis showed that CatA and CES1 are both expressed in primary human hepatocytes. However, expression of CES1 is undetectable in clone A replicon cells. Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis. Hydrolysis of the ester is followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the spontaneous elimination of phenol and the production of an alaninyl phosphate metabolite, PSI-352707, which is common to both isomers. The removal of the amino acid moiety of PSI-352707 is catalyzed by histidine triad nucleotide-binding protein 1 (Hint1) to give the 5'-monophosphate form, PSI-7411. siRNA-mediated Hint1 knockdown studies further indicate that Hint1 is, at least in part, responsible for converting PSI-352707 to PSI-7411. PSI-7411 is then consecutively phosphorylated to the diphosphate, PSI-7410, and to the active triphosphate metabolite, PSI-7409, by UMP-CMP kinase and nucleoside diphosphate kinase, respectively.
Article
The ProTide technology is a prodrug approach developed for the efficient intracellular delivery of nucleoside analogue monophosphates and monophosphonates. In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an aromatic group and an amino acid ester moiety, which are enzymatically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species. Structurally, this represents the current end-point of an extensive medicinal chemistry endeavour that spans almost three decades. It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today. This technology has been extensively employed in drug discovery and it has already led to the discovery of two FDA-approved (antiviral) ProTides. In this work, we will review the development of the ProTide technology, its application in drug discovery and its role in the improvement of drug delivery and efficacy.
Article
Since loss of function mutations of PINK1 lead to early-onset Parkinson's disease, there has been growing interest in the discovery of small molecules that amplify the kinase activity of PINK1. We herein report the design, synthesis, serum stability and hydrolysis of four kinetin riboside ProTides. These ProTides, along with kinetin riboside, activated PINK1 in cells independent of mitochondrial depolarization. This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.
Article
The masking of nucleoside phosphate and phosphonate groups by an aryl motif and an amino acid ester, nowadays known as the 'ProTide' technology, has proven to be effective in the discovery of nucleotide therapeutics. Indeed, this technology, which was invented by Chris McGuigan in the early 1990s, has inspired the discovery of two FDA-approved antiviral nucleotide drugs, and many more are currently undergoing (pre)clinical development. The usefulness of this technology in the discovery of nucleotide therapeutics is showcased in this Highlight by discussing the ProTides development and the various ProTides that have reached clinical trials.
Article
Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms. We have synthesized a series of gemcitabine phosphoramidate prodrugs and screened for cytostatic activity in a range of different tumor cell lines. Among the synthesized compounds, one in particular (NUC-1031, 6f) was shown to be potent in vitro. Importantly, compared with gemcitabine, 6f activation was significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it was resistant to cytidine deaminase-mediated degradation. Moreover, 6f showed a significant reduction in tumor volumes in vivo in pancreatic cancer xenografts. The ProTide 6f is now in clinical development with encouraging efficacy signals in a Phase I/II study, which strongly supports the ProTide approach to generate promising new anti-cancer agents.
Article
O-Glycosylation is one of the most important post-translational modifications of proteins. The attachment of carbohydrates to the peptide backbone influences the conformation as well as the solubility of the conjugates and can even be essential for binding to specific ligands in cell-cell interactions or for active transport over membranes. This makes glycopeptides an interesting class of compounds for medical applications. To enhance the long-term availability of these molecules in vivo, the stabilization of the glycosidic bond between the amino acid residue and the carbohydrate is of interest. The described modular approach affords β-linked C-glycosyl amino acids by a sequence of Petasis olefination of glyconolactones, stereoselective hydroboration and a mild B-alkyl-Suzuki coupling reaction. The coupling products were transformed to C-glycosyl amino acid building-blocks suitable for solid-phase synthesis and successfully incorporated into a partial sequence of the tumor-associated MUC1-glycopeptide. The resulting C-glycopeptides are candidates for the development of long-term stable mimics of O-glycopeptide vaccines.
Article
The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Using phosphoserine-oriented peptide libraries to probe all mammalian and yeast 14-3-3s, we identified two different binding motifs, RSXpSXP and RXY/FXpSXP, present in nearly all known 14-3-3 binding proteins. The crystal structure of 14-3-3zeta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 A resolution. The bound peptide is in an extended conformation, with a tight turn created by the pS +2 Pro in a cis conformation. Sites of peptide-protein interaction in the complex rationalize the peptide library results. Finally, we show that the 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl.
Article
Many protein-protein interactions in cells are mediated by functional domains that recognize and bind to motifs containing phosphorylated serine and threonine residues. To create small molecules that inhibit such interactions, we developed methodology for the synthesis of a prodrug that generates a phosphoserine peptidomimetic in cells. For this study, we synthesized a small molecule inhibitor of 14-3-3 proteins that incorporates a nonhydrolyzable difluoromethylenephosphoserine prodrug moiety. The prodrug is cytotoxic at low micromolar concentrations when applied to cancer cells and induces caspase activation resulting in apoptosis. The prodrug reverses the 14-3-3-mediated inhibition of FOXO3a resulting from its phosphorylation by Akt1 in a concentration-dependent manner that correlates well with its ability to inhibit cell growth. This methodology can be applied to target a variety of proteins containing phosphoserine and other phosphoamino acid binding domains.
Article
The way to a 14-3-3 binder: A fragment-based combinatorial small-molecule microarray generates affinity-based fingerprints of the 14-3-3σ protein. One small molecule (see picture; in red box) that disrupts the 14-3-3/protein interaction (green/blue) has been identified. The compound is cell-permeable and possesses both in vitro and in-cell activities.
Article
2'-Beta-D-arabinouridine (AraU), the uridine analogue of the anticancer agent AraC, was synthesized and evaluated for antiviral activity and cytotoxicity. In addition, a series of AraU monophosphate prodrugs in the form of triester phosphoramidates (ProTides) were also synthesized and tested against a range of viruses, leukaemia and solid tumour cell lines. Unfortunately, neither the parent compound (AraU) nor any of its ProTides showed antiviral activity, nor potent inhibitory activity against any of the cancer cell lines. Therefore, the metabolism of AraU phosphoramidates to release AraU monophosphate was investigated. The results showed carboxypeptidase Y, hog liver esterase and crude CEM tumor cell extracts to hydrolyse the ester motif of phosphoramidates with subsequent loss of the aryl group, while molecular modelling studies suggested that the AraU l-alanine aminoacyl phosphate derivative might not be a good substrate for the phosphoramidase enzyme Hint-1. These findings are in agreement with the observed disappearance of intact prodrug and concomitant appearance of the corresponding phosphoramidate intermediate derivative in CEM cell extracts without measurable formation of araU monophosphate. These findings may explain the poor antiviral/cytostatic potential of the prodrugs.